MicroRNA expression as a predictive marker for gemcitabine response after surgical resection of pancreatic cancer

Kenoki Ohuchida, Kazuhiro Mizumoto, Tadashi Kayashima, Hayato Fujita, Taiki Moriyama, Takao Ohtsuka, Junji Ueda, Eishi Nagai, Makoto Hashizume, Masao Tanaka

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

Background: To improve the prognosis of patients after resection of pancreatic cancer, the most appropriate and efficient treatment should be provided to specific subsets of patients. Our aim was to identify promising microRNAs as markers to predict responses to gemcitabine in patients with resected pancreatic cancer. Methods: Two gemcitabine-resistant pancreatic cancer cell lines were established, and global microRNA expression analyses was performed by quantitative reverse transcription-polymerase chain reaction (qRT-PCR). Eleven miRNAs were selected as putative predictive markers and analyzed by means of macrodissected formalin-fixed, paraffin-embedded samples obtained from 90 patients with or without gemcitabine treatment after resection of pancreatic cancer. Results: We identified 24 microRNAs whose expression was altered in gemcitabine-resistant cells. qRT-PCR analyses showed that patients with high miR-142-5p and miR-204 expression had significantly longer survival times than those with low miR-142-5p (P = 0.0077) and miR-204 (P = 0.0054) expression in the gemcitabine-treated group. This was not seen in the nontreated group. Multivariate analyses showed that miR-142-5p expression was an independent prognostic marker only in patients treated with gemcitabine (P = 0.034). Conclusions: miR-142-5p is a promising predictive marker for gemcitabine response in patients with resected pancreatic cancer.

Original languageEnglish
Pages (from-to)2381-2387
Number of pages7
JournalAnnals of Surgical Oncology
Volume18
Issue number8
DOIs
Publication statusPublished - Aug 1 2011

Fingerprint

gemcitabine
MicroRNAs
Pancreatic Neoplasms
Reverse Transcription
Polymerase Chain Reaction
Paraffin
Formaldehyde
Multivariate Analysis

All Science Journal Classification (ASJC) codes

  • Surgery
  • Oncology

Cite this

MicroRNA expression as a predictive marker for gemcitabine response after surgical resection of pancreatic cancer. / Ohuchida, Kenoki; Mizumoto, Kazuhiro; Kayashima, Tadashi; Fujita, Hayato; Moriyama, Taiki; Ohtsuka, Takao; Ueda, Junji; Nagai, Eishi; Hashizume, Makoto; Tanaka, Masao.

In: Annals of Surgical Oncology, Vol. 18, No. 8, 01.08.2011, p. 2381-2387.

Research output: Contribution to journalArticle

@article{cb4aa356bb4b48e29fb65a31d62971b0,
title = "MicroRNA expression as a predictive marker for gemcitabine response after surgical resection of pancreatic cancer",
abstract = "Background: To improve the prognosis of patients after resection of pancreatic cancer, the most appropriate and efficient treatment should be provided to specific subsets of patients. Our aim was to identify promising microRNAs as markers to predict responses to gemcitabine in patients with resected pancreatic cancer. Methods: Two gemcitabine-resistant pancreatic cancer cell lines were established, and global microRNA expression analyses was performed by quantitative reverse transcription-polymerase chain reaction (qRT-PCR). Eleven miRNAs were selected as putative predictive markers and analyzed by means of macrodissected formalin-fixed, paraffin-embedded samples obtained from 90 patients with or without gemcitabine treatment after resection of pancreatic cancer. Results: We identified 24 microRNAs whose expression was altered in gemcitabine-resistant cells. qRT-PCR analyses showed that patients with high miR-142-5p and miR-204 expression had significantly longer survival times than those with low miR-142-5p (P = 0.0077) and miR-204 (P = 0.0054) expression in the gemcitabine-treated group. This was not seen in the nontreated group. Multivariate analyses showed that miR-142-5p expression was an independent prognostic marker only in patients treated with gemcitabine (P = 0.034). Conclusions: miR-142-5p is a promising predictive marker for gemcitabine response in patients with resected pancreatic cancer.",
author = "Kenoki Ohuchida and Kazuhiro Mizumoto and Tadashi Kayashima and Hayato Fujita and Taiki Moriyama and Takao Ohtsuka and Junji Ueda and Eishi Nagai and Makoto Hashizume and Masao Tanaka",
year = "2011",
month = "8",
day = "1",
doi = "10.1245/s10434-011-1602-x",
language = "English",
volume = "18",
pages = "2381--2387",
journal = "Annals of Surgical Oncology",
issn = "1068-9265",
publisher = "Springer New York",
number = "8",

}

TY - JOUR

T1 - MicroRNA expression as a predictive marker for gemcitabine response after surgical resection of pancreatic cancer

AU - Ohuchida, Kenoki

AU - Mizumoto, Kazuhiro

AU - Kayashima, Tadashi

AU - Fujita, Hayato

AU - Moriyama, Taiki

AU - Ohtsuka, Takao

AU - Ueda, Junji

AU - Nagai, Eishi

AU - Hashizume, Makoto

AU - Tanaka, Masao

PY - 2011/8/1

Y1 - 2011/8/1

N2 - Background: To improve the prognosis of patients after resection of pancreatic cancer, the most appropriate and efficient treatment should be provided to specific subsets of patients. Our aim was to identify promising microRNAs as markers to predict responses to gemcitabine in patients with resected pancreatic cancer. Methods: Two gemcitabine-resistant pancreatic cancer cell lines were established, and global microRNA expression analyses was performed by quantitative reverse transcription-polymerase chain reaction (qRT-PCR). Eleven miRNAs were selected as putative predictive markers and analyzed by means of macrodissected formalin-fixed, paraffin-embedded samples obtained from 90 patients with or without gemcitabine treatment after resection of pancreatic cancer. Results: We identified 24 microRNAs whose expression was altered in gemcitabine-resistant cells. qRT-PCR analyses showed that patients with high miR-142-5p and miR-204 expression had significantly longer survival times than those with low miR-142-5p (P = 0.0077) and miR-204 (P = 0.0054) expression in the gemcitabine-treated group. This was not seen in the nontreated group. Multivariate analyses showed that miR-142-5p expression was an independent prognostic marker only in patients treated with gemcitabine (P = 0.034). Conclusions: miR-142-5p is a promising predictive marker for gemcitabine response in patients with resected pancreatic cancer.

AB - Background: To improve the prognosis of patients after resection of pancreatic cancer, the most appropriate and efficient treatment should be provided to specific subsets of patients. Our aim was to identify promising microRNAs as markers to predict responses to gemcitabine in patients with resected pancreatic cancer. Methods: Two gemcitabine-resistant pancreatic cancer cell lines were established, and global microRNA expression analyses was performed by quantitative reverse transcription-polymerase chain reaction (qRT-PCR). Eleven miRNAs were selected as putative predictive markers and analyzed by means of macrodissected formalin-fixed, paraffin-embedded samples obtained from 90 patients with or without gemcitabine treatment after resection of pancreatic cancer. Results: We identified 24 microRNAs whose expression was altered in gemcitabine-resistant cells. qRT-PCR analyses showed that patients with high miR-142-5p and miR-204 expression had significantly longer survival times than those with low miR-142-5p (P = 0.0077) and miR-204 (P = 0.0054) expression in the gemcitabine-treated group. This was not seen in the nontreated group. Multivariate analyses showed that miR-142-5p expression was an independent prognostic marker only in patients treated with gemcitabine (P = 0.034). Conclusions: miR-142-5p is a promising predictive marker for gemcitabine response in patients with resected pancreatic cancer.

UR - http://www.scopus.com/inward/record.url?scp=80051552504&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80051552504&partnerID=8YFLogxK

U2 - 10.1245/s10434-011-1602-x

DO - 10.1245/s10434-011-1602-x

M3 - Article

C2 - 21347785

AN - SCOPUS:80051552504

VL - 18

SP - 2381

EP - 2387

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

SN - 1068-9265

IS - 8

ER -